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Summary
Study objectives: To study prognostic value of different biochemical markers for morphological progression of early knee osteoarthritis.
Design: A total of 89 patients with knee osteoarthritis (OA) were enroled into the study. The follow-up period was 2 years. Radiological OA
progression was evaluated by measuring joint space width. Pentosidine was detected using the HPLC method described earlier, cartilage
oligomeric matrix protein (COMP) using the method published by our team. MMP-9, tissue inhibitors of metalloproteinases (TIMP), YKL-40
and hyaluronic acid were detected using commercially available kits.
Results: In the group of patients suffering from knee OA, higher serum levels of pentosidine (P=0.04), MMP-9 (P=0.02), TIMP (P=0.04) and
COMP (P=0.05) were detected compared with healthy control subjects. Using a correlation analysis method, it has been found that the
patients with higher basic serum levels of hyaluronic acid had a faster radiological progression (r=0.56, P<0.005), as well as the patients with
higher basic serum pentosidine levels (r=0.30, P<0.005). Other biochemical markers had no statistically significant prognostic value.
Conclusions: In our study, serum levels of hyaluronic acid and pentosidine had a predictive value for further development of knee OA in that
further joint space narrowing was detected in the patients with knee OA in the next 2 years.
© 2004 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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Introduction
Osteoarthritis (OA) is the most common joint condition
affecting up to 12% of the population1. Its prevalence in the
population of 65 years of age and over is almost 50%. OA
often causes disability resulting in enormous financial costs
of the therapy, including final surgical treatment.
The American College of Rheumatology (ACR) has
published the criteria for diagnosis and classification of OA.
However, these are not convenient for the detection of early
OA stages2–4.
Also, the evaluation of OA progression has not been
successfully addressed despite different organizations
such as OARSI (Osteoarthritis Research Society
International)5 or OMERACT (Outcome Measures In
Rheumatoid Arthritis Clinical Trials)6 publishing their ‘Rec-
ommendations’. These outcomes may be classified as
indicators evaluating the symptoms (pain and functions),
and indicators of the morphological seriousness and pro-
gression of the disease7. There has been a common view
that in order to be able to evaluate the effectiveness of
chondroprotective therapy, or ‘structurally modifying drugs’
as they are also called5, it is necessary to identify a
morphological criterion. Although such methods as MRI
scan8 and ultrasound are being tested at present, the only
validated indicator is still a flat X-ray image.
Recently a debate has been stirred concerning the most
advantageous radiological equipment and techniques for
OA progression evaluation9. The debate mainly concerns
knee joints. There have been reports that most investi-
gators now prefer imaging in semiflexion10, both assisted
and unassisted, with the help of fluoroscopy, and a digital
computer assessment of the joint space width11. However,
no clearly defined X-ray protocol has yet been published.
Biochemical OA markers represent a relatively new
and rapidly developing research field. The possibility for
using these markers for early OA diagnosis and prognostic
evaluation as well as the methods of OA progression were
proposed more than 15 years ago. The international
GREES group has proposed the following points of interest
which should be addressed by future trials studying
biological markers12:
a use them as surrogate indicators for diagnosis, in
addition to X-ray,
b identify healthy persons with a possible risk of OA,
c predict the development of early stages (both treated
and untreated),
d evaluate OA progression.
The most complicated task is to identify and select
suitable biochemical markers. OA is a structurally complex
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disease manifesting itself by the destruction of joint carti-
lage, subchondral bone, sclerosis and cysts, osteophytes
and synovial inflammation. Cartilage destruction is consid-
ered to be the most important and primary event and
therefore cartilage attracts most of the attention. However,
it is also important to take other joint tissues into account.
Biochemical markers may be classified according to
several aspects. According to their origin, it is possible to
classify the markers as originating from cartilage, bone, or
as markers reflecting synovial inflammation. The advan-
tage of the marker would be its specificity to a certain
tissue. However, this is mostly not the case. The markers
may further be specified as indicators of degradation,
indicators of synthesis and pure indicators of inflammation.
Another classification of the markers is according to the
compartment in which they may be detected: serum, urine
and synovial fluid. During the last year, pentosidine a new
potential indicator has been identified13.
Increased biochemical marker levels have been ident-
ified e.g. in the serum or urine of OA patients compared
with healthy control subjects in proteoglycan monomer
fragments14, keratansulphate15, cartilage oligomeric matrix
protein (COMP)16, C telopeptide collagen II17, hyaluronic
acid18, CRP19, YKL 4020, metalloproteinases21 and pyridi-
noline22. Predictive biochemical marker values for OA
progression have been published for COMP23, hyaluronic
acid, CRP and TIMP24,25.
The main objectives of our study were to: (a) perform a
longitudinal clinical and morphological study of OA progres-
sion in early/moderate OA and look for a correlation be-
tween clinical and different morphological indicators (RTG,
MRI, ultrasound and scintigraphy), (b) evaluate a battery of
potential biochemical OA markers and to express a stand-
point with regard to their value as predictive morphological
progression indicators. In this study, the results will be
presented which correlate biochemical markers with struc-
tural damage. The correlation with clinical parameters will
be the subject of the next publication.
Methods
In the longitudinal study, patients were followed for 2
years. The patients were examined at the beginning and at
the end of the evaluated time period.
PATIENTS
Patients with knee OA according to the ACR criteria were
enroled into the study2,3 all had baseline radiographs and
have proven osteophytes. These were symptomatic
patients with a reported pain during the last month. The
disease duration (from its diagnosing) did not exceed 3
years. Each patient has provided his/her written consent
with the participation in the study. In the control group we
used 20 volunteers employed in the Institute whose mean
age was the same as that of the studied group and who did
not suffer from clinically manifest osteoarthritis of the knee
or other joints. Blood sera from healthy volunteers were
only taken at baseline for ethical reasons.
RADIOLOGICAL EVALUATION
For X-ray imaging, a technique with knee in extension
was used in order to achieve maximum standardization, as
we described earlier27.
The joint space width was measured at the narrowest
point in the medial compartment of the femorotibial joint.
For measuring, a 0.1 mm caliper and magnifying glasses
was used. Each image was read by two experienced
radiologists who did not know which of the images was first
or last. This method, described by Lequesne28, has been
modified at our Institute29. When using this method, a
so-called intraobserver error was 3.6% and interobserver
error was 6.5%. In addition to the measurement of the joint
space when evaluating OA progression, we also used the
atlas published by R. Altman30. For bilateral affection, the
knee which was in a worse clinical state was selected for
examination.
BIOCHEMICAL MARKERS
After the collection, the blood samples were centrifuged
and the serums were frozen at −70°C until their final
processing.
COMP was determined using a sandwich ELISA mono-
clonal antibodies 17-C10 and 16-F1231. Intra and inter
essay variance of the method has been established as 8%
and 10% respectively.
ELISA MMP-9, MMP-13 AND TIMP-1
The levels of matrix metalloproteinases MMP-9 and
MMP-13 and of their tissue inhibitor TIMP-1 were detected
by the ELISA method, using kits produced by the Biotrak/
Amersham Biosciences Company. To detect MMP-9 and
TIMP-1, ELISA plates were covered with the serums diluted
at 1:20, to detect MMP-13 undiluted serums were used.
Each sample was applied into two pits. The concentrations
were evaluated using a computer program of the ELISA
reader Sun Rise supplied by the Schoeller Instruments
company.
PENTOSIDINE
Serum pentosidine was detected by a method published
by us earlier13,40 which is based on high-pressure liquid
chromatography (HPLC) in reversion phase. Pentosidine
(PEN) monitoring was performed using a fluorescent de-
tector at excitation and emission wavelength EX/EM=335/
385 nm, column temperature was 40°C, mobile phase flow
rate was 0.5 ml/min. A brief method description: 1 ml of the
sample (serum, urine) was mixed with 1 ml of concentrated
HCl (35%) and hydrolyzed at 105°C over the period of 16 h.
Preliminary hydrolyzate refining (0.5 ml) was performed
with spheric cellulose CC31 by selective sorption in 15 ml
of n-butylalcohol – acetic acid – water mixture (8-1-1) and
by desorption using 3 ml 0.05 M HCl. The hydrolyzate was
evaporated and after being dissolved in 250 µl of the
mobile phase, was applied into the HPLC column in the
amount of 10 µl. The reproducibility of the HPLC evaluation
was 1%, reproducibility of the entire method (i.e. including
hydrolyzation and refining) 4.44%, recovery was 77±3.5%
and sensitiveness limit was 17.6 femtomols.
STATISTICAL ANALYSIS
The comparison of OA patients with healthy control
subjects was performed using the t-test.
The correlation of biochemical markers with joint space
narrowing was performed using a correlation coefficient in
linear regression.
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Results
A total of 100 patients were enroled into the study of
which 89 patients presented themselves for the final exami-
nation after 2 years. There were 59 females and 30 males
(Table I). The mean age was approximately 57 years and
the mean disease duration was 2.9 years.
RADIOLOGICAL PROGRESSION EVALUATION
The joint space width was 4.95±1.46 mm at the begin-
ning of the study and 4.55±1.58 mm at the end of the study.
The mean joint space narrowing was 0.4±0.79 mm over the
period of 2 years, which corresponds with a mean yearly
progression of 0.2 mm.
BIOCHEMICAL MARKERS
Table II shows the comparison of biochemical marker
values at the beginning and end of the study between
the entire group of patients with osteoarthritis and the
healthy control subjects. At the beginning of the study,
higher values of pentosidine (143.4±99.0 nmol/l vs
115.3±34.3 nmol/l, P=0.04), MMP-9 (147.1±101.4 mg/ml vs
97.9±67.0, P=0.02), TIMP (872.7±155.1 ng/ml vs 781.8±
145.7 ng/ml, P=0.04) and of COMP (1063.2±626.4 ng/ml
vs 1022.9±6460 ng/mol, P=0.05) were detected. At the
end of the study, only the values of the following markers
were significant compared with control subjects: MMP-9
(150.7±131.9 vs 97.9±67 ng/ml, P=0.05) and COMP
(1235.5±647.5 vs 1022.9±646.0 ng/ml, P=0.04). No
significant changes were registered during the 2-year
period.
We have also performed a correlation of individual bio-
chemical marker values in relation to the narrowing of the
joint space. A significant relation has been detected for the
correlation between the initial values of hyaluronic acid and
joint space narrowing during the next 2 years (r=0.56)
(P<0.005) but not for hyaluronic acid values at the end of
the study (r=0.06) (Fig. 1). Basic pentosidine levels (r=0.30)
(P<0.005) had a significant relation to further joint space
narrowing and a positive relation was also detected at the
end of the study (r=0. 34, P=0.005) (Fig. 2). No correlation
has been found between initial and final COMP levels and
joint space narrowing (Fig. 3).
Discussion
The objective of our study was mainly to identify the
importance of so-called biochemical markers for OA pro-
gression. A group of patients suffering from primary knee
OA of a relatively early stage (<3 years) were selected for
the study.
Joint space narrowing over a 2-year period was 0.4 mm,
which corresponds with 0.2 mm a year. Literature data on a
mean yearly joint space narrowing differ substantially (10
times) ranging from 0.06 to 0.6 mm/year32. In our previous
studies, we detected a yearly joint space narrowing rate of
only 0.1 mm/year27,29. Apart from the used technique, the
yearly joint space narrowing rate also depends on patients
selected for the study. In our study, the patients suffered
from more severe symptoms than in previous studies. As to
radiological technique, the patients’ knees were in exten-
sion when making X-ray images, the reason for it being an
uncertainty at the beginning of the study (and virtually to the
present time) as to which semiflexion techniques is the
most advantageous for longitudinal patient studies33.
One of the possibly important features of biochemical OA
markers is their potential as a diagnostic tool. In accord-
ance with a published literature, we found higher COMP16,
TIMP26 and MMP 934 values in patients with OA. The
finding of higher pentosidine levels in OA patients
compared to healthy control subjects is relatively new.
Table I
Demographic characteristic of the OA patients with knee joints (N=89)
Mean±SD Controls
Males/females 30/59 8/12
Age (year) 56.7±7.2 51.7±6.4
Disease duration (years) 2.9±1.8 –
BMI 28.6±4.6 27.8±5.2
Joint space at the beginning of the study 4.95±1.46 –
Joint space narrowing over 2 years (mm) −0.40±0.79 –
Table II
Biochemical markers in patients with knee OA*
Indicator Study beginning Study end Controls
Value P 1 Value P 2
Hyaluronic acid (ng/ml) 30.2±19.6 NS 27.1±16.6 0.1 32.5±20.6
Pentosidine (nmol/l) 143.4±99.0 0.04 125.6±76.9 NS 115.3±34.0
YKL-40 (ng/ml) 59.0±34.9 NS 64.0±41.7 NS 65.8±35.3
MMP-9 (ng/ml) 147.1±101.4 0.02 150.7±131.9 0.05 97.9±67.0
TIMP (ng/ml) 872.7±155.1 0.04 833.8±161.8 NS 781.8±145.7
COMP (ng/ml) 1063.2±626.4 0.05 1235.5±647.5 0.04 1022.9±646.0
*N=89. MMP-9: Metalloproteinase 9; MMP-13: metalloproteinase 13; TIMP: tissue inhibiters of metalloproteinases; COMP: cartilage
oligomeric matrix protein; P 1: significance, t-test of the original value compared with control values; P 2: final values compared with control
values.
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However, despite the fact that these values were signifi-
cantly higher in the group with OA compared with the
control group, the clinical importance of the observation is
disputable. The differences are higher only to a certain
extent and in so-called healthy control subjects there is
such a variance in the values that their importance for an
individual patient is rather low.
Apart from the diagnostic importance of biochemical
markers also their prognostic value is being considered.
In this study, a higher progression risk of OA progression
was posed by increased serum hyaluronic acid values,
which is, however, predominantly a marker of synovial
inflammation. A prognostic value of serum hyaluronic acid































































Fig. 2. Correlation between serum pentosidine levels and knee joint space narrowing in patients with OA during 2 years.
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Final glycation products (advanced glycation end-
products – AGE) have enjoyed the attention of researchers
in the last 10 years35. Of the AGE group, one of the
best-defined products is pentosidine detectable by the
HPLC method. AGE have been studied in connection
with aging36 but have also been detected in a number of
other diseases such as renal insufficiency37 or rheumatoid
arthritis38. Recently, De Grott et al.39 has found AGE
accumulation in joint cartilage which had a negative impact
on the balance of synthesis and degradation of extra-
cellular matrix proteoglycans. Recently, Sˇ pacek et al. has
detected only insignificantly higher urine pentosidine levels
in knee OA patients compared with healthy control subjects
However, after the surgery of the joint affected by the
arthritic process, a significant decrease in urine pentosidine
levels was detected13. Pentosidine serum levels are not
tissue specific, but were found in another study correlation
of pentosidine and COMP in synovial fluid41. We have
found in the same study, correlation of pentosidine in
synovial fluid and serum (r2=0.7, P<0.001) but no corre-
lation in COMP levels in synovial fluid and serum
(r2=0.00092). We suggest that pentosidine may be a more
suitable putative local marker of cartilage pathology than
COMP.
To establish a potential prognostic value of pentosidine,
which has been reported in this study, further trials will be
required.
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